ºû¥Í¯ÀE¼vÅT®a¸Vªº¬¡¤O¤Î§K¬Ì¤ÏÀ³

¤ý¥¿´Ü

´f³Ó·»¾¯´£ªo¼tªÑ¥÷¦³­­¤½¥q

¡@¡@ºû¥Í¯À E ¬OÀu¨}ªº®a¸VÀç¾i¤§¥²»Ý­n¯À¡CµM¦Ó¡A¥¦ªº¯u¥¿­«­n©Ê«oÂA¬°¤Hª¾¡C¥»¤å¤D¦b±´°Q¡G(1)¨j¹å¤ÆªºÂúÂû¤§¬¡¤O¡A(2)ÂúÂû©è§Ü¶Ç¬V©Ê¯e¯fªº¤ÏÀ³¡A(3)ºû¥Í¯À E¡BÖ´ ( Se ) »P§K¬Ì¤TªÌªº¬Û¤¬Ãö«Y¡A(4)ºò­¢ªº®ÄÀ³¡A¥H¤Î (5)ºû¥Í¯À E §êºtªº¨¤¦â¡C

¤Þ¡@¡@¨¥

¡@¡@³\¦h¤£¦Pªº«OÅ@¾÷¨î¤w¸g³Q¯Ç¤J¦b®a¸V¥Í³J­p¹ºªº½d³ò¤¤¡A¦Ó¥B½T«O­F­L¨ì¹å¤Æ®É±o¥H¦s¬¡ªº¾÷¨î¤]³Q¬ã¨s¡CRomanff ¤À§O¦b 1949 ¦~¤Î 1972 ¦~µoªí¤F¦³Ãö¥Û¦Ç½èªº³J´ß¤Î³J´ß½¤¯à°÷±Æ°£·L¥Íª«ªº«I¤J¡A¥H¤Î³J¥Õ·|ªý¤î·L¥Íª«ªº¥Íªø¡C¦Ó 1961 ¦~ Kent¡A1963 ¦~ Karthigasu & Jenkin¡A1964 ¦~ Karthigasu µ¥¤H¡A1966 ¦~ Solomon ¤Î 1973 ¦~ Mizejewski µ¥¤H¡A¥ý«á¬ã¨s¥X¦å²G¤¤¤j¶qªº¬y°Ê¥Õ¦å²y ( Leucocytes ) ©Mºôª¬¤º¥Ö¨t²Î ( Reticuloendothelial  system ²ºÙ RES ) ¤¤ªº¥¨¾½²Ó­M ( macrophages ) ²Õ¦¨¤F¤@ºØ«D¯S²§©Êªº²Ó­M©Ê¨¾¿m¾÷ºc ( nonspecific  cellular  defense ) ¨Ó²M°£¦Ñ¤Æ²Ó­Mªº­F­L©M¥~¨Óª«½è¡C³oºØ«OÅ@¾÷¨î·|¦]¤zÂZ¤¸ ( interferon )¡A¸ÉÅé ( complement )¡A½Õ²z¯À ( opsonins ) ©M¥À©Ê§ÜÅé ( maternal   antibodies ) ªº¥X²{¦Ó¥[±j¨ä¾÷¨î¬¡©Ê¡C

¡@

(¤@)®a¸Vªº§K¬Ì¨t²Î

¡@¡@Glick ¦b 1977 ¦~¤Î 1978 ¦~¡A¦Ó 1979 ¦~ Shields µ¥¤H¤Î 1980 ¦~ Kendaal ³£³°³°ÄòÄòÃÒ¹ê¤F¡A§K¬Ì¨t²Î ( the  immune  system ) ªºµo¨|¬O¤@­Ó½ÆÂø¡B¯A¤Î¼sªxªº¹Lµ{¡A¥¦¥]¬A¤Fªì¯Å²O¤Ú²Õ´©M¦¸¯Å²O¤Ú²Õ´ªº¦X¨Öµo¨| ( concurrent  development )¡A¥H¤Î¥]²[¤F¤£¦P²O¤Ú®É´Áªº¼W¥Í»P¤À¤Æ¤§²O¤Ú¥ý½è²Ó­M ( Lymphoid  progenitor  cells ) ªº§Î¦¨¡C­FÅé¥~ªº§Z¶ÀÅn ( extra - embryonic  yolk  sac. ) ©M­FÅ餺ªº³y¦å¾÷ºc ( intra - embryonic   hemopoietic  sites ) ²£¥Í¤F¦h·¥©Êªº¦å¤¤ºØ­ì²Ó­M ( multipotential   blood  stem  cells )¡AµM«á²¾¥X¨Ã´å¨«¨ì¥¿¦bµo¨|ªº¯Ý¸¢ ( thymus )¡B·Æ¤óÅn ( bursa  of  Fabricius )¡BµÊŦ ( spleen )¡B°©Åè ( bone  marrow )¤Î¨ä¥L¥¼¨Óªº³y¦å²Õ´¤§°òÅé ( rudiments )¡C¹Ï¤@Åã¥Ü¥X®a¸V§K¬Ì¨t²Îªº¦­´Áµo¨|¡C¥]¬A¤F¤T­Ó¶¥¬q¡G

(1)·L¤pÀô¹Òªºµo¨| ( Development  of   microenvironment )¡F

(2)²O¤Ú²Ó­Mªº¥Í¦¨ ( Lymphocytogenesis )¡F

(3)¥\¯à¬Û ( Functional  phase )¡C

¡@

058906-29.gif (11336 bytes)

¡@

¡@¡@¦b¯Ý¸¢ªº·L¤pÀô¹Ò¤¤¡A²O¤Ú¥ý½è²Ó­M¥ý¶i¦æ³s¦X ( committed )¡A¦A¸g¥Ñ T ²Ó­M¶i¤@¨Bªº¼W¥Í¡B¤À¤Æ¡A¹F¦¨²Ó­M¤¤¶¡©Ê§K¬Ìªº¥\¯à ( Cell - medium   immune  functions )¡C¦Ó¥t¥~¤@¨ÇºØ­ì²Ó­M ( s - cell ) ¶i¤J·Æ¤óÅn¤¤¡A¼W¥Í¡B¤À¤Æ¦¨ B ²Ó­M¦X¦¨ªÌ¡V¡V§K¬Ì²y³J¥Õ ( Ig ) ªº¤£¦P«¬¦¡¦P·½ª«½è ( clones )¡V¡VÅé²G§K¬Ì ( humoral  immunity ) ªº¨ü°Ê¾¹²Ó­M ( effector  cells )¡CT ²Ó­M©M B ²Ó­MÂ÷¶}¤Fªì¯Å²O¤Ú¤W¥Ö¾¹©x ( lymphoepithelial  organs )¡A´å¨«¨ìµÊŦ©M¦¸¯Å²O¤Ú²Õ´¤¤¡A¶i¦æ§ó¶i¤@¨Bªº¤À¤Æ©MÀò±o§Ü­ì ( antigen ) ¤ÏÀ³ªº¯à¤O¡C¤@¥¹­±Á{§Y±N¹å¤Æ¤§»Ú¡A¥~³ò²O¤Ú²Õ´ ( Peripheral  lymphoid ) ¤¤±M¥q§K¬Ì¤Î¨ä¥LªþÄݪº²Ó­M¼Æ¥Ø¡A¨ì¹F¤@­ÓìH­È ( threshold  level ) ®É¡A§K¬Ì¯à¤O´N·|«Ü®e©ö¦aªí²{¥X¨Ó¡C

¡@

(¤G)ºû¥Í¯À E ªº¥À©Ê²¾§Î ( maternal  carry - over ) »P¤pÂûªº§K¬Ì

¡@¡@³Ìªñ¦³¤@¨Ç¬ã¨s³ø§i«ü¥X¡Aºû¥Í¯À E ¹ï¤pÂûªº§K¬Ì¨t²Î¡A¬O¤@ºØ¦³®Äªº¨ë¿E¯À¡C¹}³¤¤´£°ªºû¥Í¯À E ªº³B²z¡A¥i¥H¼W¥[¤pÂûªº§K¬Ì¤ÏÀ³¡A¤]¼W¥[¤F¹ï¤j¸z±ìµß ( Escherichia   coli ) «I¥Çªº©è§Ü¤O¡C

¡@¡@1952 ¦~ Buxton¡B1971 ¦~ Gaultney µ¥¤H³£¥Ñ¸ÕÅç¬ã¨s±o¨ì¥H¤Uªºµ²½×¡A¨º´N¬O¤pÂûªº§ÜÅé¡A¬O¥ÀÂû¸g§Z¶ÀÅn¡A¥H³Q°Ê¹B¿é ( passively  transfer ) ¶Çµ¹¤pÂûªº¡C

¡@¡@1978 ¦~ Jackson µ¥¤H¡A¤]±o¨ì¬Û¦Pªºµ²½×¡A¥L­Ì±q¸ÕÅ礤±oª¾¡A·í¹}³¤¤²K¥[ 150 ©M 450 ²@§J¡þ¤½¤çºû¥Í¯À E¡AÁý¹}¥ÀÂû¥i¥H¹ï¥¬¤ó¬y²£±ìµß ( Brucella   abortus ) ¦³«Ü¦nªº§K¬Ì§@¥Î¤§®É¡A¤]¹ï 2 ¤éÄÖ©M 7 ¤éÄÖ¤pÂû¦å¼ß¤¤¡A¸g¥Ñ³Q°Ê¹B¿éªº²¾§Î§ÜÅ馳ÅãµÛ¼W¥[ªºÁͶաCµM¦Ó¡A°²¦p¥H 90¡B300 ¤Î 900 ²@§J¡þ¤½¤çºû¥Í¯À E ªº¹}³Áý¹}¥¼¨ã§K¬Ì§@¥Îªº¥ÀÂû¡A«h¤pÂû±o¤£¨ì¸û¨Îªº§ÜÅé»ù ( ant   ibody  titers )¡C©Ò¥H¡A¥H¾A·í¿@«×ªººû¥Í¯À E ²K¥[¡AÁý¹}¤w¨ã§K¬Ì§@¥Îªº¥ÀÂû¡A¥i¥H§ïµ½¤pÂûªº§ÜÅé»ù¨Ã½á¤©¸û¨Îªº«OÅ@§@¥Î¡C

¡@¡@1979 ¦~ Nockels ¤]´£¥X¸ò Jackson ¬ÛÃþ¦üµ²ªGªº³ø§i¡Aªí¥Ü¥ÀÂû¹}Áý 150 ©Î 450 IU¡þ¤½¤çºû¥Í¯À E ªº¹}³®É¡A2 ¤éÄÖ©M 7 ¤éÄÖªº¤pÂû¦³©úÅã´£°ª§ÜÅé§t¶qªº¶É¦V¡A( P<0.01 )¡C¦Ó¥B 7 ¤éÄÖªº¤pÂû¤ñ 2 ¤éÄÖªº¤pÂû§t¦³¸û§C¶qªº§ÜÅé»ù¡A( P<0.01 ) ( ¨£ªí 1 )¡C¥ÀÂûÁý¹}¤£¦P§t¶qªººû¥Í¯À E¡A¤Ï¬M¦b¤pÂûªº¥Íª«¬Û¤§§ÜÅé¤ÏÀ³ ( biophasic  ant  ibody  response ) ¤è­±¡C

¡@

ªí 1.    ¥ÀÂûÁý¹}ºû¥Í¯À E¡A¹ï¤pÂû³Q°Ê¦aÀò±o§K¬Ì§@¥Îªº®ÄÀ³ a

¥À  ©Ê  ¤¤

ºû¥Í¯À E ¤§§t¶q

¼W²K¶q IU¡þ¤½¤ç

2  ¤é  ÄÖ 7  ¤é  ÄÖ
¤p  Âû

¼Æ  ¥Ø

¾®¶°¯À»ùb

log2

¤p  Âû

¼Æ  ¥Ø

¾®¶°¯À»ù

log2

0

90

150

300

450

900

26

31

22

20

21

14

2.68 Ac

2.94 ABC

3.18 BC

2.59 A

3.34 C

2.79 A

50

62

38

40

40

31

2.16 A

2.18 A

2.65 B

2.12 A

2.62 B

2.19 A

a¡B¥ÀÂû¦b¹å³J¤§«e¥|¬P´Á¡A¤w¸g¥H¥¬¤ó¬y²£±ìµß¹ê¬I¦Ù¦×§K¬Ì ( immunized  intramuscularly )¡C

b¡B¥»³B²z¤¤ 2 ¤éÄ֤Π7 ¤éÄÖªº¾®¶°¯À»ù¤£ºÉ¬Û¦P ( P<0.01 )¡C

c¡B¥­§¡­È«á¤£¦Pªº­^¤å¤j¼g¦r¥À¡Aªí¥Ü®t²§ÅãµÛ ( P<0.01 )¡C

¡@

¡@¡@Nockels ¤S°µ¤F²K¥[ 6 ºØ§t¶q¤§ºû¥Í¯À E ªº¤é³¡AÁý¹}¨S¦³§K¬Ì§@¥Îªº¥ÀÂû¡A¹ï¤pÂû§K¬Ì¤ÏÀ³ªº¼vÅT¤§¸ÕÅç¡A¥L±o¨ì¤@¨Çµ²½×¡Aµ²½×¬O¨S¦³³Q§K¬Ìªº¤pÂû¡A´N¨S¦³©úÅ㪺§ÜÅé»ù¡C¥u¦³±qÁý¹} 450 IU¡þ¤½¤çºû¥Í¯À E ¹}³ªº¥ÀÂû©Ò²£¥Íªº³Q§K¬Ìªº 21 ¤éÄÖ©M 28 ¤éÄÖ¤pÂû¡A¤~¦³¤ñ¹ï·Ó²Õ§óÅãµÛ¼W¥[ªº¾®¶°¯À»ù ( agglutinin  titers ) ¥X²{¡A( ¤À§O¬OP<0.01 ¤Î P<0.05 ) ( ¨£ªí 2 )¡C¦Ó¥B¡A³o¥i¥H¤Ï¬M¥X¥Ñ¥ÀÂûªººû¥Í¯À E Âಾ¨ì¤pÂûªººôª¬¤º¥Ö¨t²Î ( RES ) ¤§¥Íª«¬Û¤ÏÀ³¡C

ªí 2.   ¥¼¨ü§K¬Ìªº¥ÀÂû¹}Áýºû¥Í¯À E¡A¹ï¤pÂû³Ìªìªº§K¬Ì¤ÏÀ³¤§®ÄÀ³

¥À  ©Ê  ¤è  ­±

ºû¥Í¯À E ªº²K

¥[¶q IU¡þ¤½¤ç

21  ¤é  ÄÖ 28  ¤é  ÄÖ
¤p  Âû

¼Æ  ¥Ø

¾®¶°¯À»ù¹ï

¼Æ­È log2

¤p  Âû

¼Æ  ¥Ø

¾®¶°¯À»ù¹ï

¼Æ­È log2

0

90

150

300

450

900

49

33

48

34

33

46

3.96 A

4.47 AB

4.07 A

3.85 A

4.91 B

4.13 A

44

31

47

36

31

41

5.72 a

5.44 a

5.61 a

5.94 a

6.37 b

5.90 a

µù¡G(1)¤pÂû©ó 14 ¤éÄ֮ɡA¹ê¬I¥¬¤ó¬y²£±ìµß¤§¦Ù¦×§K¬Ì¡C

        (2)¥»³B²z©ó 21©M 28¤éÄֱĦå´ú¦å²y¾®¶°»ù¡C

        (3)¥­§¡­È«á¤£¦Pªº­^¤å¦r¥À¤j¼g¡Aªí¥Ü®t²§ªºÅãµÛ©Ê ( P<0.01 )¡C¦Ó¤p¼g¦r¥Àªí P<0.05 ªº®t²§ÅãµÛ©Ê¡C

        (4)¸ê®Æ¨Ó·½¡GNockels ( 1979 )¡C

¡@

(¤T)ºû¥Í¯À E ©M¶Ç¬V©Ê¯e¯fªº©è§Ü¤O

¡@¡@ÁöµM¤w¸gª¾¹Dºû¥Í¯À E ¥i¥H¨ë¿E§ÜÅé¤ÏÀ³¡A¦ý¬O³o¨Ã¤£·N¨ýµÛ¤@©w¥i¥H¦Ê¤À¤§¦Ê¦a§ïµ½¯e¯fªº©è§Ü¤O¡C©ó¬O¡A¦³¨Ç±M®a´NµÛ¤â¤@¨t¦Cªº¬ã¨s¡A¬ã¨s°²¨Ï²K¥[¹L¶qªººû¥Í¯À E¡A¹ï¥¿±`¥Íªøªº»Ý¨D©M¯à§_²£¥Í°Êª«¬Y¨Ç¯f­ì ( Pathogens ) ªº©è§Ü¤Oªº®ÄÀ³¡C

¡@¡@®Ú¾Ú«Ü¦h¬ã¨s³ø§i«ü¥X¡Aºû¥Í¯À E ªº¯Ê¥F¡A¨Ã¤£·|¾É­P§K¬Ì¤ÏÀ³ªº¶Ë®`¡CµM¦Ó¡A¥t¤@¤è­±¤]¦³±M®a­Ì¤@­P»{¬°¨Ï¥Î¹L¶qªººû¥Í¯À E¡A¥i¥H¹ï§ÜÅ骺²£¥Í¦³¨ë¿E©Êªº¼vÅT¡A¤×¨ä¬O§K¬Ì²y³J¥Õ G ( IgG ) ªº²£¥Í¡C¤ä«ù³o¨Ç½×ÂIªº±M®a§ó¶i¤@¨B´£¥X¡A¨Ï¥Îºû¥Í¯À E ¥i¥H¼W¶iºôª¬¤º¥Ö¨t²Î ( RES ) ªº§]¾½§@¥Î¤§¬¡©Ê¡A¼W¥[µÊŦªº­«¶q¡A¥H¤ÎµÊŦ¤º²£¥Í§ÜÅ骺²Ó­M¼Æ¥Ø¤]·|¼W¥[¡C

¡@¡@ºû¥Í¯À E ¦ü¥G¥i¥HÂǵۼW¥[ Ubiquinones ªº¦X¦¨¡A¨Ó¨ë¿E¨¾¿m¾÷¨î¡A¦]¬° Ubiquinones ¯à°÷¼W¥[ºôª¬¤º¥Ö¨t²Î ( RES ) ªº§]¾½§@¥Î¤§¬¡©Ê¡Cºû¥Í¯À E ªº«OÅ@®Ä¯à­nÂk¥\©ó¨â­Ó¥D­nªº¦]¤l¡Ga. Åé²G§K¬Ìªº´£°ª¡A©M b. §]¾½§@¥Îªº¨ë¿E¡C

¡@¡@µL½×¦b¸ÕºÞ¤º©Î¦b¬¡Å餺¸ÕÅç¡Aºû¥Í¯À E ³£¥i¥H´£°ª¦Ñ¹«©M¤pÂûªº§ÜÅé§Î¦¨²Ó­M ( §Y¦å¤pªO Plaque §Î¦¨²Ó­M ) ¤§¼Æ¥Ø¡A¦Ó¥B´£°ª§K¬Ì²y³J¥Õ G ( IgG ) ©M§K¬Ì²y³J¥Õ M ( IgM ) ªº§ÜÅé»ù¡Cºû¥Í¯À E ¤]´£°ª¤F¯S²§©ÊÅé²G§K¬Ì¤ÏÀ³©M²Ó­M¤¤¶¡©Ê§K¬Ì¤ÏÀ³¡A´N¹³¬O¥»¯à©Êªº©è§Ü¯e¯f¡A¯S§O¬O§]¾½§@¥Î¡C

¡@¡@1981 ¦~ Tengerdy µ¥¤H»{¬°ºû¥Í¯À E ¨Ï¥Î¨ì¤ñ²{¦æ¥Í²£ªº¹}³§t¶q°ª 3 ~ 6 ­¿ªº¾¯¶q¡A©Î¹³¨C¤é±ÀÂ˶qªºÃľ¯®É¡A¬O«Ü¦³®Ä²vªº¡Cºû¥Í¯À E §@¥Î¤§¾÷¨î¥]¬A¤F (1)¤@¯ë©Êªº§Ü®ñ¤Æ¾¯®ÄÀ³ ( General  antioxidant   effect )¡A¥i¥Hªý¤î¹L®ñ¤Æ§@¥Î ( Peroxidation ) ©Mªý¼¸¦Û¥Ñ°ò ( Free   radical ) ¶Ë®`¨ì±Ó·Pªº²O¤Ú¤W¥Ö²Ó­M ( Lymphoreticular  cells )¡F(2)¯S²§©Êªº§Ü®ñ¤Æ¾¯®ÄÀ³ ( Specific  antioxiolant  effect )¡A¦b©óÂǵ۪ý¤î L - arachidonic   acid ªº®ñ¤Æ§@¥Î¡A©M¼vÅT®ñ¤ÆÁC»Ä¤Æ ( Oxidative  phosphorylation ) §@¥ÎªºÃöÁä»Ã¯À ( Key  enzyme )¡A¨Ò¦p¤zÂZ»²úA Q ( Coenzyme  Q ) ©M²Ó­M¦â¯À ( Cytochrome ) ªº¥Í¦X¦¨¡A¦Ó¥B¤]ÂǵۧïÅܲO¤Ú²Ó­Mªº²Ó­M½¤¤§·P¨ü¾¹¥\¯à ( Receptor   function )¡A¨Ó§í¨î«e¦C¸¢¯Àªº¥Í¦X¦¨¤ÏÀ³¡C

¡@¡@

(¥|)¤pÂû¹ï¤j¸z±ìµß ( E. Coli ) ªº¤ÏÀ³

¡@¡@1974 ¦~ Heinzerling µ¥¤H«ü¥X¡A·í¤pÂû©M¤õÂû·P¬V¤j¸z±ìµß ( Escherichia  coli ) ®É¡AÁý¹}²K¥[ºû¥Í¯À E ¹}³¡A¥i¥H­°§C¦º¤`²v©M¼W¥[¦å²y¾®¶°¤ÏÀ³»ù ( hemo - agglutination ( HA ) reaction  titers )¡C³o¨Çµ²ªG¥¿¦pªí 3¡A¤G­Ó¸ÕÅ礤©ÒÅã¥Üªº¡AÁý¹}®Æ²K¥[ 150 ©Î 300 IU¡þ¤½¤çºû¥Í¯À E ªº¹}³¡A½T¹ê¥i¥H«ÜÅãµÛ¦a­°§C¦º¤`²v ( P<0.01 )¡C¦Ó¥B¸ÕÅç 1 ¤¤Åã¥Ü¥X¡Aºû¥Í¯À E ¹ï¤G¶gÄÖ¤pÂûªºÅé¼W­«¦³©úÅã¦Ó¦³§Qªº¼vÅT ( P<0.01 )¡A¦ý¸ÕÅç 2 «hµL¦¹²{¶H¡C

ªí 3    ¤w·P¬V¤j¸z±ìµßªº¤pÂû¡Aºû¥Í¯À E ¹ï¨ä¥Íªø¡B¦º¤`²v¡B

¦å²y¾®¶°»ù©M¦å²M²y³J¥Õ¤ñ²v

ºû¥Í¯À E

²K  ¥[  ¶q

IU¡þ¤½¤ç

¤p Âû

¼Æ ¥Ø

¦º¤`²v 2 ~ 4 ¶g

¥­§¡¼W­«

( §J )

¦å²y¾®¶°

»ù¹ï¼Æ­È

log2

¦å²M²y³J¥Õ¤ñ²v¡A%
£\1 £\2 £]1 £^1
¸Õ     Åç      ¤@
0

150

300

36

34

37

25.0 B

9.3 A

5.4 A

284 B

313 A

330 A

7.75 B

10.75 A

10.00 A

4.9 a

4.0 a

3.7 a

12.2 a

13.3 b

15.5 b

16.0 a

12.8 b

11.8 b

18.9 a

19.0 a

20.7 a

¸Õ      Åç      ¤G
0

150

300

42

40

40

31.0 B

4.9 A

0.0 A

395 A

367 A

387 A

6.66 B

8.83 A

9.66 A

2.8 a

4.8 a

3.4 a

13.5 a

19.3 a

16.1 b

14.5 a

12.3 a

11.9 b

16.9 a

18.9 a

17.7 a

µù¡G(1)¤pÂû©ó 15 ¤éÄ֮ɡA¦b«á¯Ý³¡®ðÅn±µºØ¤j¸z±ìµß¡F©ó 29 ¤éÄÖ¤§¤pÂû±Ä¦å´ú¦å²y¾®¶°»ù¡C¦Ó¦å²M²y³J¥Õªº¤ñ²v¡A¸ÕÅç¤@¤¤¥H¨C³B²z²Õ 4 °¦¤p Âû¨Ó´ú©w¡A¸ÕÅç¤G¤¤¥H¨C³B²z²Õ 5 °¦¤pÂû¨Ó´ú©w¡C

(2)¥­§¡­È«á­±ªº¤j¼g¦r¥À¡A¥Nªí P<0.01 ®Éªº®t²§ÅãµÛ©Ê¥­§¡­È«á­±ªº¤p¼g¦r¥À¡A¥Nªí P<0.05 ®Éªº®t²§ÅãµÛ©Ê

(3)¸ê®Æ¨Ó·½¡GHeinzerling µ¥¤H ( 1974 )

¡@

¡@¡@³o¤G­Ó¸ÕÅç©Ò²£¥ÍÅé¼W­«ªº®t²§¡A¥i¯àªº¸ÑÄÀ¬O¦º¤`²vªº¤£¦P©Ò¾É­Pªº¡C¸ÕÅç¤@¤¤¡A¦]¬°³Q·P¬VÂû°¦ªº«ì´_±¡§Î¡A¥¿¦p¬¡ÂûÅé¼W­«­°§C±¡§Î¤@¼Ë¦a©úÅã¡A©Ò¥H¦³¸û¤Öªº³Q·P¬V¤pÂûµo¥Í¦º¤`¡C¦b¥¼¨ü·P¬Vªº±±¨î²Õ¤¤¡AµÊŦ©M·Æ¤óÅnªº­«¶q´N¹³Åé­«ªº¦Ê¤À¤ñ¡A¨S¦³¦]ºû¥Í¯À E ªº²K¥[¦Ó¦³©Ò§ïÅÜ¡C¤£ºÞ¦p¦ó¡A¦bµÊŦ­«¶q¤è­±¡A²K¥[ºû¥Í¯À E »P¤£²K¥[ºû¥Í¯À E¡A³£¨S¦³ÅãµÛ®t²§¡C

¡@¡@·í¨ü·P¬Vªº¤pÂû¼W¥[ºû¥Í¯À E ªº²K¥[¶q¡A¥i¥HÅãµÛ¦a¼W¥[¦å²y¾®¶°§ÜÅé»ù¡A¦Ó¥B¹ï©ó¦º¤`²v­°§C¤]¦³¬Û¦Pªºµ²ªG¡C¼W¥[¹}³¤¤ºû¥Í¯À E ªº§t¶q¡A¤]¾É­P¤pÂû¹ï¤j¸z±ìµßªº£\¡V¦å²M²y³J¥Õ¤ñ²v ( £\¡VSerum   globulin  fraction ) ¤j¤j¦a´£°ª¡A( P<0.05 )¡C¦Ó¤£ºÞ¬O§_³Q·P¬V¡A²K¥[ºû¥Í¯À E ·|¨Ï £]¡V¦å²M²y³J¥Õ¤ñ²v ( beta - serum  globulin  fraction ) ÅãµÛ¦a­°§C¡A( P<0.05 )¡C³o¨Çµ²ªG·t¥ÜµÛ¤pÂûÊï§Ü¤j¸z±ìµß·P¬Vªº«OÅ@¯à¤O¼W¥[¡A¥i¯à¬O¹}³¤¤²K¥[ºû¥Í¯À E¡A©Ò³y¦¨Åé²G©Ê§K¬Ì¤ÏÀ³´£°ªªº½t¬G¡C

¡@

(¤­)¤pÂû¹ï²yÂίgªº¤ÏÀ³

¡@¡@1981 ¦~ March µ¥¤H«ü¥X¡A¤pÂû¹ïºû¥Í¯À E ©ÎÖ´ ( Se ) ªº¯Ê¥F±¡§Î¡A©Î¬O¦¹¤GªÌ¹ï§K¬Ì¥\¯àªº­×Å@±¡§Î¡A¥i¥HÂǵ۹ï¦Ï¬õ¦å²y ( erythrocytes ) ªºÅé²G¤ÏÀ³´ú©w¥X¨Ó¡Cºû¥Í¯À E ©MÖ´ ( Se ) ªº¯Ê¥F¡A´î¤Ö¤F·Æ¤óÅnªº­«¶q¡A¤]­°§C¤Fªì¯Å²O¤Ú¾¹©x©MµÊŦ¤¤ªº²O¤Ú²y¤§Á`¼Æ¡A¦Ó¥B·|¤Þ°_³o¨Ç²Õ´¤º³¡§ïÅܪº¯}Ãa¡C

¡@¡@1984 ¦~ Colnago µ¥¤H±q¥|­Ó¹êÅ礤±o¨ìµ²½×¡A·í¹}³¤¤²K¥[Ö´ ( Se ) 0.25 ²@§J¡þ¤½¤ç©Îºû¥Í¯À E 100 ²@§J¡þ¤½¤ç®É¡A¹ï¨S¦³³Q§K¬Ì¦Ó¨ü E - tenella ·P¬Vªº¤pÂû¡A·|­°§C¨ä¦º¤`²v©M¼W¥[¨äÅé¼W­«¡C¤]´N¬O»¡Ö´ ( Se ) ©Îºû¥Í¯À E ªº²K¥[¡A¹ï¤pÂû©è§Ü²y¤¤«Iŧªº§K¬Ì¯à¤O¦³¼W°ªªº§@¥Î¡C

¡@

(¤»)ºû¥Í¯À E¡BÖ´ ( Se ) ¤Î§K¬Ì

¡@¡@ºû¥Í¯À E ¬O¬¡¤Æ¦¸²Ó­M½¤ ( vital  subcellular   membranes ) ¹ï§Ü¹L®ñ¤Æª«ªº¶Ë®`¤§²Ä¤@¹D¨¾½u¡CÖ´ ( Se ) «h¸g¥Ñ¾¢®ò°ò²¸¹L®ñ¤ÆúA ( glutathoine  peroxides ) ªº§@¥Î¡A¯}Ãa¤F¥ô¦óÂǺû¥Í¯À E ¨¾¿m¾÷¨î©ÒÀò±oªº¹L®ñ¤Æª«¡A¦]¦¹¦³ªý¤î¹L®ñ¤Æª«µo¥Í³sÂê¤ÏÀ³¡B¯}Ãa¬¡¤Æ²B²¸°ò¤ÆúA ( vital  sulfhydryl  enyzmes )¡A¥H¤Î¶Ë®`¨ä¥L¦³Ãö§K©ó¯e¯f¦Óºû«ù°Êª«Àç¾i°·±d¥²»Ýªº¨t²Îµ¥¥\¯à¡C

¡@¡@ºû¥Í¯À E ©MÖ´ ( Se ) ªº¥\¯à¡A³Q»{¬°¦b©óºûÅ@¬õ¦å²y²Ó­M½¤ ( erythrocyte  membrane ) ¤§§¹¾ã©Ê¡C¥Ñ¹Ï¤G¤¤±oª¾¡A¬õ¦å²y²Ó­M©M²O¤Ú²Ó­M³£¬O°_·½©ó¤@¯ëªº¦h¥\¯à¤§ºØ­ì²Ó­M ( common  pluripotential  stem  cells )¡A³o­Ó¨Æ¹êÃÒ¹ê¤Fºû¥Í¯À E ©MÖ´ ( Se ) »P²O¤Ú²Ó­Mªº²Ó­M½¤¬y³q©Ê ( membranes  fluidity ) ¦³ÃöÁpªº·§©À°ò¦¡A¦]¦¹¥i¥H±Àª¾ºû¥Í¯À E¡BÖ´ ( Se ) ¹ï¼vÅT§K¬Ì¤ÏÀ³¾÷¨îªº§@¥Î¤]¬O¤@¼Ë¡C

¡@¡@±q 1972 ¦~¨ì 1977 ¦~ Tengerdy¡ASpallholz¡ABrown ¤Î Berber µ¥¤H¡A¤À§Oªº¬ã¨sµ²ªG¡A³£¤@­P¤ä«ù¤W­zªº°²³]¡C¦b¥L­Ì³Ìªìªº¬ã¨s¤¤¡A«ü¥X¤F¹}³¤¤ºû¥Í¯À E ¼W¥[¤­­¿®É¡A¤pÂû©è§Ü¦Ï¬õ¦å²yªºÅé²G©Ê§K¬Ì¤ÏÀ³·|¼W±j¡C¥L­Ì¤]»{¬°ºû¥Í¯À E ªº§K¬Ì¨ë¿E©Ê ( immunostimulation ) ¸ò¨ä§Ü®ñ¤Æ¾¯¤§§@¥Î¦³±K¤ÁÃö«Y¡C¦Ó³oºØ§K¬Ì¯à¤O¦b¦Ñ¹«©M¤ÑªÇ¹«ªº¸ÕÅ礤¤]ªí²{¥X¨Ó¡C§K¬Ì¤ÏÀ³ªº¨ë¿E©Ê¹ï¥¼­P¬¡¤§¯S®í§Ü­ì ( nonliving  particulate  antigens ) ¨Ã¨S¦³­­¨î¡A¹ï¤j¸z±ìµß¦Ó¨¥¡A¨Ï¥Îµ}ÄÀªº©e¤º·ç©Ô«~¨t°¨ªº¸£ª¢¬Ì­] ( venezuelan  equine  encephalitis  virus  vaccine ) ¤]¦³¬Û¦üªº®ÄªG¡C

¡@¡@1973 ¦~ Spallholz ¤Î 1984 ¦~ Colnago µ¥¤H»{¬°¡A¦pªG¹}³¤¤§â°ª©ó±ÀÂ˶qªºÖ´ ( Se ) ²K¥[¤J¡A·í§@Àç¾iªº»Ý¨D¶q¡A«h¥i¥H¼W±jªì¯Å§K¬Ì¤ÏÀ³¡C³oºØµ²ªG¤D®Ú¾Ú§ÜÅé§Î¦¨²Ó­Mªº¼Æ¥Ø©M¦Ï¬õ¦å²y¾®¶°§ÜÅ骺¿@«×´ú©w¥X¨Óªº¡CµM¦Ó¡AÖ´ ( Se ) ªº¨ë¿E§@¥Î»P±J¥Dºû¥Í¯À E ªºÀç¾i¼Ð·ÇµLÃö¡C

¡@¡@²K¥[ºû¥Í¯À E ¥i¥H¨ë¿E§K¬Ì²y³J¥Õ G ( IgG ) ¦X¦¨¤§®ÄÀ³¡A¬Û¹ï¦aÖ´ ( Se ) ¥i¥H«P¶i§K¬Ì²y³J¥Õ M ( IgM ) ¥Í¦¨²Ó­Mªº¼W¥[¤Î IgM §ÜÅ骺¦X¦¨¼W¥[¡C¦Ó¥B¡A«Ü¦³½ìªº¬O·í¹}³¿@«×²K¥[¦Ü»Ý¨D¶qªº 10 ~ 30 ­¿®É¡A®ÄªG³Ì¦n¡C¥i¬O¡A¹ï¨ä¥LºØÃþªº­÷¨Å°Êª«¦Ó¨¥¡A¬O§_·|¤¤¬r¡A¨º´N­È±o°Óºe¡C

¡@

(¤C)ºò­¢ ( stress ) »P§K¬Ì¤ÏÀ³

¡@¡@¥Ñ©óÂû°¦¦³©è§Ü¾D¨üªººØºØºò­¢©M±N¹}®ÆÂà´«¦¨°ª«~½èªº¦×©M³J¤§¯à¤O¡A©Ò¥H®a¸V¨Æ·~¤´µM»]»]¤é¤W¡C¦Ó³\¦h¤£¦P§Î¦¡ªººò­¢¹ï¹}¾iªº®a¸V¬O«Ü¤jªº§xÂZ¡C

¡@¡@1950 ¦~ Selye ¬ã¨s¥X¤@®M²z½×¡A¥Î¨Ó¸ÑÄÀ°Êª«¦³¾÷Åé¹ïºò­¢ªºµ{«×»PºØÃþªº¤£¦P¤ÏÀ³±¡§Î¡C®Ú¾Ú³o­Ó²z½×¡A¤@¨Ç³æ¤@ªººò­¢¡A½Ñ¦p´H§NÀô¹Ò¡B¹}³¤¤³æ¤@Àç¾i¯Àªº³¡¥÷¯Ê¥F¡B©ÎªÌ¬O°Êª«¨t²Î¤Wªº§ïÅÜ©Ò¤Þ°_ªº»´·L¯e¯fª¬ªp¡A³Ìªì¤Þ°_¤@­ÓÅå·W©Ê¤ÏÀ³ ( alarm  reaction )¡A«á¨Ó´N¦ñÀHµÛ¤@­Ó¾AÀ³©Ê¤ÏÀ³ ( adoptation   reaction )¡A¥L§â³oºØ¹ïºò­¢ªº¤ÏÀ³ºÙ¤§¬°¤@¯ë©Êªº¾AÀ³¯à¤Oºî¦X¯gª¬ ( General  adaptation  syndrome )¡C

¦Ó®Ú¾Ú 1964 ¦~ Von  Faber ©Ò´£ªº¤pÂû¥NÁ¤§§ïÅÜ»Pºî¦X¯gª¬ªºÁp·Q¡G

(1)¸£¤U¸¢«e¸­ ( anterior  pituitary  gland ) ªºªÎ¤j¡A¥i¯à¬O¥Ñ©óµÇ¤W¸¢¥Ö½è¯À ( adreno - corticotrophic  hormone   ( ACTH ) ªº¤Àªc¼W¥[¤§½t¬G¡C

(2)µÇŦ¸~¤j¡A°_¦]©ó¤º³¡ªºªÎ¤j¡C

(3)µÇŦªºÁx©T¾J´î¤Ö¡A»PµÇ¤W¸¢¥Ö½è¯À ( ACTH ) ªº¤Àªc¼W¥[¬O¦P®Éµo¥Íªº¡C

(4)²O¤Ú°h¤Æ¡C¤]´N¬O¹ï¥®¸V¨Ó»¡¡A¯Ý¸¢¡B·Æ¤óÅn¤ÎµÊŦªºµäÁY¬Oºò­¢µo¥Í³Ì±Ó·Pªº«ü¼Ð¡C¦Ó¦¨¸V¤§·Æ¤óÅn®ø¥¢¡A¬O©Ê¸¢Ãþ©T¾Jªº¼vÅT¡C

(5)¥Õ¦å²y´`Àôªº§ïÅÜ¡C§Y¬O²O¤Ú²yªº´î¤Ö©M²§¶Ý©Ê²Ó­M ( beterophils ) ªº¼W¥[¡C

(6)¦å¤¤ÂfÂc»Ä§t¶qªº¼W¥[¡C

(7)¥Íªø¿ð½w©ÎÅé­«´î»´¡C

¡@¡@°²¦pºC©Êªººò­¢¤£¬O¤Ó±j¯Pªº¸Ü¡A°Êª«±N¥i§¹¥þªº¾AÀ³¡A¦Ó¥B¥Íªø©Mµo¨|¨S¦³¤Ó¤j¤£¦P¡CµM¦Ó¡A°²¦p¦P®É¾D¨ü¨âºØºò­¢¡A°Êª«±N·|Ãø¥H¾AÀ³¡CÁaµM¡A¨â­Ó¦P®Éµo¥Íªººò­¢¤£¤ñ³æ¤@ºò­¢¨Ó±o±j¯Pªº±¡ªp¤U¡A¨ÌµM¥i¯à·|³y¦¨¦º¤`¡C

¡@¡@©Ò¥H®Ú¾Ú³oºØ²z½×¡A§Y¨Ï¹}³µo¥Í¥²»Ýºû¥Í¯À©ÎÓi°ò»Ä»´·L¯Ê¥F®É¡A°Êª«¤´¯à¬Û·í¥¿±`¦aµo¨|¥Íªø¡C

¡@¡@µM¦Ó¡A°²­Y¤pÂû¥¿­±Á{¥h¾AÀ³¤@ºØÀç¾i¤W¯Ê¥Fªººò­¢®É¡A¬ðµM¶¡¾D¨ü¨ì²yÂίf©Î¨ä¥L¯e¯fªº«Iŧ¡A¨º»ò§Y¨Ï¨Ï¥ÎÀç¾i¨¬°÷ªº¹}³¡A¯e¯f¤]¥¼¹FÄY­«­P¦ºªº¤pÂû¡A¦¹®É¤]¥i¯à·|¤Þ°_¦º¤`¡C¯e¯f¬O¤@ºØºò­¢¡AÀç¾iªº¯Ê¥F¬O¤@ºØºò­¢¡B´H§N¡BµjÅË ( cramped )¡B¦Ç¹Ð¦h¡B¹}¾i¹L±K¡B³q­·¡B»êż¡B¼éÀã©M¤£µÎ¾AªºÀô¹Ò±ø¥ó¤]³£¬Oºò­¢¡F±µºØ¬Ì­]¡B°Å¼L·|µo¥Íºò­¢¡FÃĪ«³B²z¤]¥i¯à²£¥Íºò­¢¡F²§±`¾¸­µ¡B¾E²¾¡BÂû°¦ªº§ì®·¡B¸ËÄx¤Î¸ü¹B¤]³£·|µo¥Íºò­¢¡C¦b¤U¦C¨âºØ¾÷¨î³~®|¤¤¡AÀô¹Ò¦]¤l¥i¯à¼vÅT®a¸Vªº§K¬Ì¤ÏÀ³¡C

(a)·í¶ÀÄT¬r¯À©M¨ä¥LÃĪ«¤Þ°_ªº¤¤¬rµo¥Í®É¡A±q¼ß²Ó­M¡B²O¤Ú²Ó­M©M¥¨¾½²Ó­M©Ò´£¨Ñ§ÜÅé¡A²Ó­M¤¤¶¡©Ê§K¬Ì©M§Ü­ìªº¹Lµ{¤¤µo¥Íª½±µªýê·|¤Þ°_ªº¨ß¬Ì§í¨î§@¥Î¡C¬r¯À¤]¥i¯à¸ò«D¯S²§¦a´£°ª¤ÏÀ³¤§¦¨¤À ( ¦p²§¶Ý©Ê²Ó­M¡B¸ÉÅé©M¨Å¨x½Å¯À ( lactoferrin ) ) °_§@¥Î¡C

(b)Àô¹Ò¦]¤l¥i¯à¸g¥ÑµÇ¤W¸¢¯À§@¥Î¡C¤]´N¬OÂǵۨë¿EµÇ¤W¸¢¥Ö½è¯À ( ACTH ) ªº¤Àªc»P¦X¦¨¡A¨Ó§í¨î ( suppress ) ©Î·»¸Ñ ( lyse ) §ÜÅé§Î¦¨²Ó­M¡C¦Ó§N¡B¼ö¡B·l¶Ë©M¹L«×¾ÖÀ½¦ü¥G´N¬O¥H³o±ø³~®|¨Ó§í¨î§K¬Ì§@¥Î¡C

1.¼öºò­¢

¦b¼öºò­¢¤U¡A®a¸V·|¨³³t¦a¤W¤ÉÅé·Å¡B§ïÅܦ夤¹q¸Ñ½è«¬ºA¤Î¤ß»P¦åºÞªº²§±`¡C

¡@¡@1979 ¦~ Cheville µo²{¦b¸ÕÅ礤¡A«æÆJªº¼öºò­¢¨Ï¤õÂû¦å¤¤¹[§t¶q«D±`©úÅã¦a¤U­°¡C¦Ó 1973 ¦~ Kohne µ¥¤H¤]³ø§i¤F¼öºò­¢¤U¡A¦åÁÞ·|³Q´£°ª¡C©Ò¥H«Øij¦b¼öºò­¢¤U­­¨î±Ä­¹¶q¡A±N¥i¥H´£°ª¦s¬¡²v¡C

¡@¡@¸ÕÅçÅã¥Ü¤pÂû¦bÀô¹Ò·Å«×°ªªº®É­Ô¡A¦bªì¯Å§Ü­ì¨ë¿E©|¥¼¶}©l¤§«e¡A¤w¸g¤Þ°_¤Fªì¯Å§K¬Ì¤ÏÀ³¾D¨üªý¼¸¡C¦¹¥~¡A¼öºò­¢¤]¤j¤j¦a­°§C¤w¸g¦s¦bªº§ÜÅé¿@«×¡C³o¦ü¥G»¡©ú¦]¼ö©Ò»¤µoªº§K¬Ì§í¨î§@¥Î¡A¤]¶¡±µ¦a¼vÅT¨ìµÇ¤W¸¢¥Ö½è²Ó­Mªº¤Àªc§@¥Î¡C

¡@¡@¨º´N¬O»¡¡A¦]¼öºò­¢¤Þ°_ªº¦å¼ß¤¤¥Ö½è¹}ଶqªº´£°ª¡A¼vÅT¤F²O¤Ú²Ó­Mªº§í¨î©Î¯}Ãa¡CMetyrapone ¬O¤@ºØµÇ¤W¸¢¥Ö½èÃþ©T¾J¦X¦¨ªºªýÂ_¾¯¡A¥i¥H´î¤Ö¼ö¤ÎµÇ¤W¸¢¥Ö½è¯À ( ACTH ) ªº§K¬Ì§í¨î®ÄÀ³¡C

2.§Nºò­¢

¡@¡@Fortier ©M De  Groot »{¬°µÇ¤W¸¢ªº¬¡©Ê¡A¸g±`³Q·í¦¨µûÂ_¥Í²zºò­¢ªº¼Ð·Ç¡Cªø´Á¼ÉÅS¦b§NÀô¹Ò¤U¡A·|«ÜÅãµÛ¦a¼W¥[§ÜÅé»ù¡Cµu®É¶¡¼ÉÅS¦b§NÀô¹Ò 2 ©Î 4 ¦¸¡A¦ñÀHµÛ§Ü­ìªºª`®g¡A·|´£°ª¾®¶°¯À©Î·»¦å¯Àªº¤ÏÀ³¯à¤O¡C³o¨Ç¸ê®Æ«ü¥X¡A§ÜÅé»ùªº´£°ª»P´H§Nª¬ºA¤Î§Ü­ìª`®gªº®É¶¡¦³±K¤ÁÃö«Y¡A¾Ú»¡´H§NªºÀô¹Ò·|¨ë¿E¤pÂû¥Òª¬¸¢ªº¬¡©Ê¡A¦Ó·Å©MªºÀô¹Ò«o·|§í¨î¥¦ªº§@¥Î¡C

3.Âû¸s±K«×ºò­¢

¡@¡@°ª±K«×¹}¾i¤UªºÂû¸s¡A®e©ö¤Þ°_¯e¯fµo¥Íªº¼W¥[¡C¾ÖÀ½ªº¼vÅT¡A³y¦¨Âû¸s¤¬¬Û¶Ç¬V¨Ã¤£·|«Ü©úÅã¡A¦ý«o¥i¥H¾É­P¤ô¡B­¹ª«©Î¹Ô®Æªº¦Ã¬V¡C¦Ó¥B¦b®a¸Vªº¥Í²z¤ÏÀ³¤è­±¡A¾ÖÀ½¦³¤@­Óª½±µªº¼vÅT¡A¨º´N¬O©Ò¿×ªº¡§ªÀ·|ºò­¢ ( social  stress )¡¨¡C³oºØªÀ·|ºò­¢¯g«á¡A¨üµÇ¤W¸¢¥Ö½è¯À¤Àªcªº¼vÅT¡C

¡@¡@Âû¸s±K«×ºò­¢¦ü¥G¹ï¶Ç¬V©Ê¤Î§K¬Ì©Ê¦³ª½±µªº¼vÅT¡C1971 ¦~ Gross ©M Colmano »{¬°¡A¤pÂûºû«ù¦b«D±`¨}¦nªºªÀ·|Àô¹Ò¤U¡A¹ï¯f¬r©Ê¶Ç¬Vªº·P¨ü¤O¤ñ¹ï²Óµß©Ê¶Ç¬Vªº·P¨ü¤O­n¨Ó±o±j¯P¡C

¥L­Ì¶i¦æ¤@³s¦êªº¸ÕÅç¡A±o¨ì¤F¤@¨Çµ²ªG±À½×¡G

(1)¦å¼ß¤¤¥Ö½èପº¿@«×´£°ª»P¤pÂû¹ï¤j¸z±ìµßªº©è§Ü¤O¡A¦³¥¿­±¼vÅTªºÃö«Y¦s¦b¡C

(2)¤pÂû¹ê¬I¥Ö½èପºª`®g¡A¥i¥H¾É­P¶Ç¬V¤j¸z±ìµßªº©è§Ü¤O¼W¥[¡C

(3)¤Æ¾Çª«½èªýº¢µÇ¤W¸¢¥Ö½è¯Àªº²£¥Í¡A·|¤Þ°_¹ï¯f¬r©Ê¶Ç¬Vªº·P¨ü¤O¼W±j¡A¦Ó­°§C¹ï¤j¸z±ìµß¶Ç¬Vªº·P¨ü¤O¡C

(4)¨ã¦³¹ïºò­¢²£¥Í§C¦å¼ß¥Ö½èତÏÀ³©Ê©M¿@«×ªº¤pÂû«~¨t¡A¬O¹ï¤j¸z±ìµß¶Ç¬V¦³¸û±j¯Pªº·P¨ü¤O¡A¦ý¬O«o¥i¥H§ó¦³®Ä¦a©è§Ü°¨¥ß§J¯f ( Marek's  disease ) ©MÅð¼ßµß¯g ( Mycoplasma  gallisepticum )¡C

4.ºû¥Í¯À E ªº¯Ê¥F

¡@¡@¯S®íºû¥Í¯Àªº¯Ê¥F¡A°¸¦Ó·|³Q°²©w¬O³y¦¨¶Ç¬V©Ê¯e¯fªº¦]¯À¡CÁöµM¡A¦³®É­Ô·|»¡¤Î§K¬Ì¨t²Î¹ï¤ÏÀ³ªº¥¢±Ñ¡A¦ý¬O¤jÅé¦Ó¨¥¡A»PÅܧó²Ó­M¥NÁ¦³Ãöªº¤£©ú½T¾÷¨î¡A¦b´£°ª·P¨ü¤O¤è­±³q±`¬O«Ü½ÆÂøªº¡C¹ï¤pÂû¨Ó»¡¡Aºû¥Í¯À E ¯Ê¥Fªº¼vÅT¬OÂÇ®a¸V¸£¯áÅ誢¯f¬r ( avian  encephalomelitis  virus ) ©Ò»¤µoªº¦º¤`²{¶H¡C

¡@¡@Cheville ©M Monlux «ü¥X¡Aºû¥Í¯À E ¯Ê¥Fªº¤pÂû¤ñ¹ï·Ó²Õªº¤pÂû¹ï®a¸V¸£¯áÅ誢¯f¬r ( AE  Virus ) ¨ã¦³µy·L®t¤@ÂIªº·P¨ü¤O¡CµM¦Ó¡A¹ï²Óµß©Ê¶Ç¬Vªº·P¨ü¤O«h¦³¬Û¤Ïªº®ÄªG¡C¹}³¤¤²K¥[ºû¥Í¯À E ( ©Î·L¥Í¯À A ) ¥i¥H­°§C¦]¤j¸z±ìµß©Ò»¤µoªº¦º¤`²v¡C³o®ÄÀ³¦³§U©ó§ÜÅé²£¥Íªº¼W¥[¡A©M¼W¥[¥¨¾½²Ó­Mªº¦X¦¨¡C´N¸ÕÅç¤W¨Ó»¡¡A·í¥ÀÂûÁý¹}ºû¥Í¯À E ®É¡A·|´£°ª¤pÂû¦å¼ß¤¤¸g¥Ñ³Q°Ê¹B¿éªº§ÜÅé¿@«×¡C

¡@

¹}®ÆÀç¾iÂø»x²Ä¤­¥U¦X­q¥»

1989¦~¤¸¤ë¸¹¦Ü1989¦~²Ä¤»´Á

¤K¤E¦~¡D²Ä¤»´Á ( 22 ~ 32 )

Copyright © 1998 ­Z¸s®n¯bªªºô. ¥»ºô¯¸¹Ï¤å«YÄÝ­Z¸s®n¦³­­¤½¥q¡A¤º¤å¤§ª©Åv¬°¸ÓÂø»xªÀ©Ò
¦³¡A«D¸g¥»¤½¥q¤Î¸ÓÂø»xªÀ¥¿¦¡®Ñ­±¦P·N¡A¤£±o±N¥þ³¡©Î³¡¤À¤º®e¡A
Âà¸ü©ó¥ô¦ó§Î¦¡´CÅé   ¡° ³Ì¨Î¸ÑªR«× 800x600
Copyright © 1998 MiobufferCo., Ltd.  All rights reserved.
Unauthorized copying and reproduction is prohibited. All trademarks property of their respective holders.